The US Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva), manufactured by Genentech, for adults with primary membranous nephropathy at risk of disease progression, providing the first FDA-approved treatment specifically indicated to induce remission of proteinuria in this population.
Obinutuzumab is a type II anti-CD20 monoclonal antibody that targets B cells involved in autoimmune disease. Its glycoengineered structure enhances antibody-dependent cellular cytotoxicity, while CD20 binding promotes B-cell depletion. The drug was previously approved for certain hematologic malignancies, lupus nephritis, and childhood-onset idiopathic nephrotic syndrome.
The approval was supported by MAJESTY, a phase 3, randomized, open-label, multicenter trial involving 142 adults with primary membranous nephropathy. Participants were assigned 1:1 to intravenous obinutuzumab or oral tacrolimus, an immunosuppressant used off-label for the condition.
The primary endpoint was complete remission of proteinuria at week 104, defined as a urine protein-to-creatinine ratio of 0.3 g/g or lower with stable estimated glomerular filtration rate (eGFR), without rescue therapy, treatment failure, or early discontinuation.
According to Genentech, 36.1% of patients receiving obinutuzumab achieved complete remission compared with 5.7% receiving tacrolimus (adjusted difference, 31.1%; 95% CI, 18.2–44.0; P<.001). Overall remission, encompassing complete or partial remission, occurred in 50% versus 12.9%, respectively, at week 104 (P<.001).
The MAJESTY investigators also reported significantly higher complete remission rates at week 76. However, the trial did not demonstrate a statistically significant difference in sustained eGFR decline of at least 30%, and subsequent endpoints in the prespecified testing hierarchy were not formally assessed for significance.
In the published trial, grade 3 or higher adverse events occurred in 22% of obinutuzumab recipients and 19% of tacrolimus recipients; serious adverse events occurred in 17% and 14%, respectively. According to the FDA, infusion-related reactions and upper respiratory tract infections were the most common side effects observed in the clinical study.
The FDA stated that obinutuzumab carries boxed warnings for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. Genentech's safety information reiterates existing precautions, including screening for hepatitis B before treatment, monitoring for reactivation during and after treatment, watching for symptoms of PML, managing infusion-related reactions, and avoiding administration in patients with active infections.
